Company news
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news
Catalyst Pharmaceuticals, Inc. news releases on 6ix. Latest, Nov 2, 2020: Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate…
Press releases — page 4
Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020
November 1, 2020
Catalyst Pharmaceuticals Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRx
October 18, 2020
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®
October 5, 2020
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal
September 28, 2020
KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity
August 25, 2020
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada
August 17, 2020
Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for "Methods of Administering 3,4-Diaminopyridine"
August 10, 2020
Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
August 9, 2020
Catalyst Pharmaceuticals’ Firdapse® (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS
August 5, 2020
Catalyst Pharmaceuticals to Hold Second Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 11th, 2020
August 2, 2020
Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders
August 2, 2020
Catalyst Pharmaceuticals Comments on Magistrate Judge's Report and Recommendation in its Lawsuit against the FDA
July 30, 2020
Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer
June 22, 2020
Catalyst Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 31, 2020
Catalyst Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 10, 2020
Catalyst Pharmaceuticals to Hold First Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 12th, 2020
May 3, 2020
Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities
April 7, 2020
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
March 15, 2020
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020
March 9, 2020
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020
February 26, 2020
Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference
February 25, 2020
Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference
February 5, 2020
Catalyst Pharmaceuticals Appoints David Ailinger as Vice President, Business Development
February 3, 2020
Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs
January 5, 2020
Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference
November 25, 2019
Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 11, 2019
Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019
October 30, 2019
Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)
October 29, 2019
Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference
September 24, 2019
Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources
September 22, 2019
Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock
September 12, 2019